

## Rhythm Biosciences enters a strategic pilot program for geneType™ with a leading Australian Pathology provider

### Highlights

- ✓ 1<sup>st</sup> strategic pilot partnership domestically for the geneType™ since Rhythm's acquisition
- ✓ Pilot program to commence in Victoria, supported by dedicated resources from both organisations, and
- ✓ Represents a key step in broadening our domestic commercial pathway of geneType™

**Melbourne, Australia, 17th July 2025:** Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company, is pleased to announce that our Genetype subsidiary business has secured its first strategic pilot partnership with a leading pathology service provider in Australia.

Both parties are committing resources to support the program's success, and this collaboration reflects a vision for advancing innovative solutions in cancer, coronary and diabetes risk assessment for personalised medicine. Importantly, the partnership creates opportunities to expand patient access to geneType™ tests through established clinical pathways. This pilot forms the basis for a broader commercial roll-out and increased future revenue opportunities for geneType™.

**Dr David Atkins, CEO & Managing Director:** " This partnership marks a significant milestone following our recent acquisition. As we ramp up education and awareness around our product's role in cancer and other health risk assessment, this collaboration serves as a crucial stepping stone towards achieving the commercial growth we envisioned with the Genetype acquisition. Partnerships of this kind will be integral to realising the benefit of many years of investment in the Genetype risk assessment portfolio and we anticipate tremendous growth ahead."

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via [investors@rhythmbio.com](mailto:investors@rhythmbio.com).

#### About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and X.

#### About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

**Rhythm Biosciences Ltd**  
ACN 619 459 335  
ASX: RHY

**Australian Registered Address**  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

#### Directors

Otto Buttula  
Sue MacLeman  
Gavin Fox-Smith  
David Atkins

Non-Executive Chairman  
Non-Executive Director  
Non-Executive Director  
CEO & Managing Director

[www.rhythmbio.com](http://www.rhythmbio.com)

E [investors@rhythmbio.com](mailto:investors@rhythmbio.com)

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

**About geneType™**

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit [www.genetype.com](http://www.genetype.com).

For personal use only